Compare Herbalife Nutrition Ltd (HLF) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

HLF trades at $14.19, up 4.26% today, with a bullish technical signal and strong analyst consensus. The stock shows attractive valuation with a P/E of 9.11 and P/S of 0.29, supported by a gross profit margin of 77.7%. Recent news includes a $250 million share repurchase program and a planned CEO transition in October 2026. Cash flow trends indicate improving operational cash generation, with 2026 projected net cash flow turning positive at $50 million.

The outlook for HLF is positive, with a consensus price target of $19.00 implying 34% upside. Risks include negative shareholder equity, high debt levels, and mixed quarterly earnings performance. Revenue stability and margin expansion efforts provide a foundation for growth, but investor caution is warranted due to ongoing leadership changes and competitive pressures in the wellness sector.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.